Clinical Trials Logo

Filter by:
NCT ID: NCT06158269 Recruiting - Multiple Myeloma Clinical Trials

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Start date: December 2023
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy

NCT ID: NCT06158217 Recruiting - Clinical trials for Invasive Breast Cancer

Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer

Start date: September 29, 2022
Phase:
Study type: Observational

Blood perfusion insufficiency and hypoxia are the main causes of drug resistance to chemotherapy in breast cancer. Increasing blood perfusion can improve drug delivery. The cavitation effect of ultrasound-stimulated microbubbles (USMBs) is known to enhance tumor blood perfusion, so we conducted a prospective human study to investigate the effects of USMBs on hemoperfusion in invasive breast cancer (IBC).

NCT ID: NCT06158087 Recruiting - Clinical trials for Intracranial Aneurysm

To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms

Start date: December 29, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess safety and effectiveness of the pEGASUS stent system.

NCT ID: NCT06158074 Recruiting - Urinary Retention Clinical Trials

Efficacy of Electrical Pudendal Nerve Stimulation and Sacral in Treating Non-obstructive Neurogenic Urinary Retention

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

To observe the clinical effects and make a comparative study between efficacy of electrical pudendal nerve stimulation (EPNS) and sacral neuromodulation (SNM) , evaluate the advantages of EPNS in the treatment of neurogenic non-obstructive urinary retention, and provide a new method for the treatment of the disease.

NCT ID: NCT06157996 Recruiting - Gastric Cancer Clinical Trials

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Start date: January 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma with PD-L1 positive and low TMEscore. A total of 92 subjects are randomly divided into study group and control group according to 1:1 ratio. Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w ± Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab ± lenvatinib is entered, and the specific dosage is the same as the treatment period. Effectiveness is assessed every 9 weeks (±7 days) until disease recurrence, metastasis, death, or loss of follow-up. The primary endpoint of this study was PFS, and secondary endpoints were OS, ORR, DoR, and DCR.

NCT ID: NCT06157827 Recruiting - Clinical trials for Advanced Neuroendocrine Carcinoma

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Start date: December 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)

NCT ID: NCT06157606 Recruiting - Weight Loss Clinical Trials

Prediction Model for Inadequate Weight Loss After Sleeve Gastrectomy

Start date: September 1, 2017
Phase:
Study type: Observational [Patient Registry]

This study aims to develop and validate a prediction model for estimating the probability of inadequate weight loss one year after sleeve gastrectomy.

NCT ID: NCT06157502 Recruiting - Clinical trials for Ischemic Stroke, Acute

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.

NCT ID: NCT06157359 Recruiting - Clinical trials for Postoperative Analgesia

Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection

Start date: November 27, 2023
Phase: N/A
Study type: Interventional

Patients with Supratentorial tumor undergoing craniotomy have a higher risk of postoperative pain, which will affect their postoperative quality of recovery (QoR). Although scalp nerve block (SNB) can alleviate postoperative pain, the effect on postoperative QoR in patients with supratentorial tumor undergoing craniotomy is still unclear. This study is aimed to explore the effect of SNB on postoperative QoR in this population. To explore the effect, we design a randomized controlled trial in which 84 patients with supratentorial tumor will be randomly assigned to either the SNB group or control group. The primary outcome is 15-item QoR score at 24 h after surgery. The secondary outcomes include 15-item QoR scores at 72 h after surgery, Riker Sedation-Agitation Scale, nausea and vomiting, intraoperative opioids and propofol consumption, perioperative heart rate and mean artery pressure, the duration of anesthesia and surgery, time to extubation, PACU duration, the length of postoperative days, adverse events within 72h and total medical expenses.

NCT ID: NCT06157346 Recruiting - Children, Only Clinical Trials

Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude

Start date: October 16, 2023
Phase:
Study type: Observational [Patient Registry]

Microbes and the human body maintain a complex relationship of interaction and influence. Different regions, altitudes, and dietary habits have different degrees of influence on the composition of children's intestinal flora. Therefore, the development and maturation process of children's intestinal flora in plateau areas was discovered, and its relationship with children's immunity, metabolism, and growth was understood. The mechanism of action of children's intestinal flora on immunity, growth and development was further analyzed by comparing it with people in low-altitude areas, to provide a scientific basis for improving children's health in plateau areas.